Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This retrospective study found that oral tofacitinib significantly reduced the severity of alopecia areata in children, achieving over a 50% reduction in hair loss severity, though relapse occurred during treatment tapering, and mild adverse effects were noted.

This study observed that some children and young adults with alopecia areata experienced flares during long-term tofacitinib treatment, despite initial successful hair regrowth.

Clotrimazole, an antifungal cream, may safely reduce skin pigmentation by breaking down the enzyme needed for making melanin.

This study identified new and recurrent missense mutations in the PHGDH and PSAT1 genes, implicating them in the pathogenesis of Neu-Laxova syndrome in Chinese patients.

This review discusses topical calcineurin inhibitors for cutaneous lupus erythematosus and reports no new clinical findings; the authors emphasize the need for more comparative studies with corticosteroids.

This case report describes two patients with ulcerative colitis and alopecia areata who did not respond to various treatments but achieved remission and improved hair growth after starting tofacitinib.

This review summarizes findings on the long-term use of tofacitinib for severe alopecia areata, reporting its potential as a promising treatment option.

This abstract lists numerous dermatological side effects and reactions associated with various medications but reports no new research findings.

This study observed that intradermal injections of Betamethasone were more effective than topical Clobetazole for treating alopecia areata in children, while Tofacitinib showed higher efficacy in those with atopic dermatitis.

In a systematic review and meta-analysis, the researchers found that intralesional triamcinolone acetonide was more effective than cryotherapy for achieving significant hair regrowth in patients with patchy alopecia areata, although both treatments had distinct safety profiles.

In this study, oral tofacitinib showed higher efficacy and tolerability in treating refractory alopecia totalis and universalis compared to traditional treatments, achieving a 50% improvement in severity scores for 44.4% of patients over six months, with fewer adverse effects.

This letter discusses the emerging use of Janus kinase inhibitors, specifically oral tofacitinib, for treating alopecia areata in children, but reports no new clinical findings.

Tofacitinib helped regrow hair in people with severe alopecia, but side effects occurred and benefits stopped after treatment ended.

This study conducted at Baghdad Teaching Hospital found that topical applications of Ciprofloxacin and Clindamycin effectively reduced acne severity indices in patients with mild to moderate acne vulgaris over 12 weeks, with Ciprofloxacin showing a greater reduction in papules and pustules compared to Clindamycin.

This study observed that oclacitinib, combined with oral glucocorticoids, achieved rapid and lasting clinical remission in four dogs with refractory juvenile-onset ischaemic dermatopathy, suggesting oclacitinib's potential as a useful immunosuppressive treatment in such cases.

This study found that intramuscular triamcinolone acetonide or pulse therapy effectively treats alopecia areata with manageable side effects, but further strategies are needed to reduce relapse rates.

This study found that tofacitinib was well tolerated and led to clinical improvement in 77% of potential responders with severe alopecia areata, alopecia totalis, or alopecia universalis.

In this study, oral tofacitinib treatment led to significant hair regrowth and changes in skin and blood biomarkers in a patient with alopecia areata.

In this study, researchers at Nottingham Children's Renal Unit found that most pediatric patients switching from Prograf to the generic tacrolimus preparation Adoport maintained stable tacrolimus levels and therapeutic effectiveness, supporting Adoport's use as a cost-saving alternative for the NHS.

This letter discusses a previous study on tofacitinib for alopecia areata, questioning its statistical analysis and suggesting that steroids may have influenced results, but it reports no new clinical findings.

This study found that combining excimer light at 308 nm with tacrolimus 0.1% was more effective in treating alopecia areata of the scalp compared to excimer light alone, as indicated by a greater reduction in the SALT score and better improvement in Treg function.

In this case report, combination therapy with topical tretinoin, topical and intralesional steroids, and systemic doxycycline showed improvement in AKN lesions for a 19-year-old man, with notable reductions in lesion size and number observed by the second week.

The combination of tretinoin, minoxidil, and betamethasone valerate may cause severe scalp inflammation.

This study reports that combining baricitinib with low-dose cyclosporine and steroids resulted in effective and safe treatment for a case of alopecia totalis, maintaining hair regrowth without adverse effects.

An 8-year-old girl with vitiligo developed extra hair growth on her knee after using tacrolimus ointment.

This retrospective study evaluated the use of tofacitinib as an induction therapy for severe alopecia areata and found it promising and comparable to the standard oral mini-pulse treatment, though pulse steroids may be considered if tofacitinib response is inadequate.

Tocilizumab might be an effective treatment for COVID-19.

This paper reviews the challenges of treating alopecia areata affecting eyelashes and discusses the risks associated with traditional therapies; it reports no new clinical results.